Does GLOFITAMAB Cause Diffuse large b-cell lymphoma recurrent? 20 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 20 reports of Diffuse large b-cell lymphoma recurrent have been filed in association with GLOFITAMAB (Columvi). This represents 1.8% of all adverse event reports for GLOFITAMAB.
20
Reports of Diffuse large b-cell lymphoma recurrent with GLOFITAMAB
1.8%
of all GLOFITAMAB reports
4
Deaths
5
Hospitalizations
How Dangerous Is Diffuse large b-cell lymphoma recurrent From GLOFITAMAB?
Of the 20 reports, 4 (20.0%) resulted in death, 5 (25.0%) required hospitalization.
Is Diffuse large b-cell lymphoma recurrent Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for GLOFITAMAB. However, 20 reports have been filed with the FAERS database.
What Other Side Effects Does GLOFITAMAB Cause?
Cytokine release syndrome (415)
Disease progression (183)
Off label use (129)
Death (125)
Neutropenia (109)
Pyrexia (78)
Febrile neutropenia (69)
Covid-19 (62)
Drug ineffective (53)
Immune effector cell-associated neurotoxicity syndrome (45)
What Other Drugs Cause Diffuse large b-cell lymphoma recurrent?
RITUXIMAB (1,359)
CYCLOPHOSPHAMIDE (1,007)
VINCRISTINE (957)
DOXORUBICIN (953)
PREDNISONE (738)
CYTARABINE (406)
DEXAMETHASONE (402)
ETOPOSIDE (375)
CISPLATIN (306)
GEMCITABINE (280)
Which GLOFITAMAB Alternatives Have Lower Diffuse large b-cell lymphoma recurrent Risk?
GLOFITAMAB vs GLOFITAMAB-GXBM
GLOFITAMAB vs GLUCAGON
GLOFITAMAB vs GLUCAGON\GLUCAGON\WATER
GLOFITAMAB vs GLUCARPIDASE
GLOFITAMAB vs GLUCOPHAGE